Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 107

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 107
---
 alternative    
 at a price at least equal to the price paid for such shares during the offer period.                                                      |

| • | If after an announcement is made, the offeror or any person acting in concert with them acquires an interest                             
 in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased accordingly. |

| • | The board of directors of the offeree company must appoint a competent independent adviser whose advice                                
 on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of 
 the offeree company.                                                                                                                   |

| • | Favorable deals for selected shareholders are not permitted, except in certain circumstances where independent                        
 shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the 
 offeree.                                                                                                                              |

| • | All shareholders must be given the same information. |

| • | Those issuing documents in connection with a takeover must include statements taking responsibility for 
 the contents thereof.                                                                                   |

| • | Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified 
 standards and must be reported on by professional advisers.                                               |

| • | Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly 
 corrected immediately.                                                                                  |

| • | Actions during the course of an offer by the offeree company, which might frustrate the offer are generally                           
 prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for 
 directors under their service contract or agreeing to sell off material parts of the target group.                                    |

| • | Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer,                                 
 including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested 
 (directly or indirectly) in 1% or more of any class of relevant securities.                                                                 |

| • | Employees of both the offeror and the offeree company and the trustees of the offeree company’s                                         
 pension scheme must be informed about an offer. In addition, the offeree company’s employee representatives and pension scheme trustees 
 have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors’         
 circular or published on a website.                                                                                                     |

| 53 |

If